

# Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S8961D3C2BE7EN.html>

Date: December 2019

Pages: 121

Price: US\$ 3,500.00 (Single User License)

ID: S8961D3C2BE7EN

## Abstracts

Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019

### SUMMARY

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5, 7, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Dermatology, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Undisclosed which include indications Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis (RRMS), Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Autoimmune Disorders, Inflammation, Psoriasis, Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Cerebral Aneurysms, Diabetic Retinopathy, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Neuroinflammation, Neuropathy, Osteoarthritis, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rett Syndrome, Sicca Syndrome (Sjogren), Stroke, Systemic Lupus Erythematosus and Unspecified.

Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Overview

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Companies Involved in Therapeutics Development

Actelion Pharmaceuticals Ltd

Akaal Pharma Pty Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

Beijing Foreland Pharma Co Ltd

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Curadim Pharma Co Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

LG Chem Ltd

Mebias Discovery LLC

Mitsubishi Tanabe Pharma Corp

Novartis AG

Oppilan Pharma Ltd

Sun Pharma Advanced Research Company Ltd

Suzhou Connect Biopharmaceuticals Ltd

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles

AK-119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKP-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amiselimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Actelion Pharmaceuticals Ltd, H2 2019  
Pipeline by Akaal Pharma Pty Ltd, H2 2019  
Pipeline by Arena Pharmaceuticals Inc, H2 2019  
Pipeline by Astellas Pharma Inc, H2 2019  
Pipeline by Beijing Foreland Pharma Co Ltd, H2 2019  
Pipeline by Boston Pharmaceuticals Inc, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Curadim Pharma Co Ltd, H2 2019  
Pipeline by GlaxoSmithKline Plc, H2 2019  
Pipeline by Idorsia Pharmaceutical Ltd, H2 2019  
Pipeline by LG Chem Ltd, H2 2019  
Pipeline by Mebias Discovery LLC, H2 2019  
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Oppilan Pharma Ltd, H2 2019  
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019  
Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Dormant Products, H2 2019 (Contd..3), H2 2019



## Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

### COMPANIES MENTIONED

Actelion Pharmaceuticals Ltd

Akaal Pharma Pty Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

Beijing Foreland Pharma Co Ltd

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Curadim Pharma Co Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

LG Chem Ltd

Mebias Discovery LLC

Mitsubishi Tanabe Pharma Corp

Novartis AG

Oppilan Pharma Ltd

Sun Pharma Advanced Research Company Ltd

Suzhou Connect Biopharmaceuticals Ltd

## I would like to order

Product name: Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S8961D3C2BE7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S8961D3C2BE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970